1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (310) 443-7300
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma
Article first published online: 2 SEP 2009
DOI: 10.1002/cncr.24576
Copyright © 2009 American Cancer Society
Additional Information
How to Cite
Glaspy, J., Atkins, M. B., Richards, J. M., Agarwala, S. S., O'Day, S., Knight, R. D., Jungnelius, J. U. and Bedikian, A. Y. (2009), Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer, 115: 5228–5236. doi: 10.1002/cncr.24576
Publication History
- Issue published online: 3 NOV 2009
- Article first published online: 2 SEP 2009
- Manuscript Revised: 22 JAN 2009
- Manuscript Accepted: 22 JAN 2009
- Manuscript Received: 3 DEC 2008
Funded by
- Celgene. Grant Number: MEL-001
References
- 1, , . Melanoma biology and new targeted therapy. Nature. 2007; 445: 851-857.
- 2, , , et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.Direct Link:
- 3, , , , , . Cutaneous malignant melanoma. Mayo Clin Proc. 2006; 81: 500-507.
- 4, , , et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007; 82: 364-380.
- 5, , , . High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000; 6( suppl 1): S11-S14.
- 6. New American Joint Commission on Cancer staging system for melanoma: prognostic impact and future directions. Surg Oncol Clin N Am. 2006; 15: 341-352.
- 7, , , et al. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc. 2007; 82: 490-513.
- 8, . Novel agents in development for the treatment of melanoma. Expert Opin Investig Drugs. 2005; 14: 885-892.
- 9, , , et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18: 158-166.
- 10, , , et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer. 2005; 103: 2584-2589.Direct Link:
- 11, , , et al. A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs. 2007; 25: 247-252.
- 12, , , et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer. 2006; 95: 581-586.
- 13, , , et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007; 30: 303-309.
- 14, , , et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000; 82: 812-817.
- 15, . Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res. 2004; 14: 57-62.
- 16, , , et al. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res. 2004; 14: 527-531.
- 17National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology™. Melanoma V. 1.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf. Accessed September 23, 2008.
- 18, , , et al. CC-1503 inhibits the expression of adhesion molecules ICAM-1 and CD44 and prevents metastasis of B16 F10 mouse melanoma cells in an animal model [abstract]. Proc Am Soc Clin Oncol. 2003; 22. Abstract 992.
- 19, , , et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004; 90: 955-961.
- 20, , , , , . Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of 3 dosing schedules in patients with solid malignancies. Eur J Cancer. 2006; 42: 2318-2325.
- 21, , , . Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000; 18: 3782-3793.
- 22, , , et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004; 54: 131-149.Direct Link:
- 23, . The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother. 2007; 8: 497-509.
- 24, , , et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008; 26: 527-534.